Calcitonin and MAP Kinase Pathways Affect CD44 in Prostate Cancer
Author Information
Author(s): Eric W. Robbins, Emily A. Travanty, Kui Yang, Kenneth A. Iczkowski
Primary Institution: University of Colorado Denver
Hypothesis
How do calcitonin and MAP kinase pathways influence CD44 expression and splicing in prostate cancer cells?
Conclusion
Calcitonin increases CD44 variant splicing in prostate cancer cells through the p38 kinase pathway.
Supporting Evidence
- Calcitonin increased CD44 variant RNA and protein levels in prostate cancer cells.
- Inhibition of protein kinase A reduced CD44 expression.
- The MEK pathway was found to increase CD44 RNA levels.
Takeaway
This study found that a hormone called calcitonin helps change a protein called CD44 in prostate cancer cells, which might help the cancer grow.
Methodology
The study assessed CD44 RNA and protein levels in prostate cancer cell lines in response to calcitonin and various kinase inhibitors.
Limitations
The study primarily focused on specific cell lines and may not fully represent all prostate cancer cases.
Statistical Information
P-Value
p = 0.01; p = 0.02; p = 0.001; p = 0.0002; p = 0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website